Liege (Belgium) - March 19, 2009, 8:30 CET - OncoMethylome Sciences SA (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) announces today that it has received the following shareholder notifications:
- Fortis Investment Management SA has increased its shareholding in the company so that it now holds more than 3% of the shares of the company
- ING Investment Management (and related mutual funds) has increased its shareholding in the company so that it now holds more than 10% of the shares of the company
- Polytechnos Venture Funds has reduced its shareholding in the company so that it now holds fewer than 3% of the shares of the company
For further details on the transparency notifications received by the company, reference is made to our website www.oncomethylome.com.
To download this press release as a PDF, click here: Press Release
About OncoMethylome Sciences
OncoMethylome Sciences SA (Euronext Brussels: ONCOB; Euronext Amsterdam: ONCOA) is a molecular diagnostics company developing gene methylation tests to assist physicians in effectively detecting and treating cancer. Specifically, the company's tests are designed to help the physician (i) accurately detect cancer in early stages of cancer development, (ii) predict a patient's response to drug therapy, and (iii) predict the likelihood of cancer recurrence.
OncoMethylome Sciences SA boasts a broad product development pipeline consisting of over ten products and a solid partnering record. The company collaborates with leading international molecular oncology research centers, such as The Johns Hopkins University, and has a number of commercial and collaborative partnerships with Veridex LLC, a Johnson & Johnson company, LabCorp, Schering-Plough Corp., GlaxoSmithKline Biologicals, Abbott, Millipore Corporation's BioScience Division, Merck KGaA, and Qiagen. OncoMethylome Sciences' products are based on methylation technology invented by Johns Hopkins University (USA).
Established in January 2003, OncoMethylome Sciences SA has offices in Liege and Leuven (Belgium), in Durham, NC (USA), and in Amsterdam (the Netherlands).
For more information please contact:
Philip Devine
Tel. +32-479-505-885
